MDM2, MDMX and P53 in Oncogenesis and Cancer Therapy

Overview

Journal Nat Rev Cancer

Specialty Oncology

Date 2013 Jan 11

PMID 23303139

Citations 605

Authors

Mark Wade

Yao-Cheng Li

Geoffrey M Wahl

Affiliations

Soon will be listed here.

Abstract

The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour suppressor. However, the MDM proteins modulate and respond to many other signalling networks in which they are embedded. Recent mechanistic studies and animal models have demonstrated how functional interactions in these networks are crucial for maintaining normal tissue homeostasis, and for determining responses to oncogenic and therapeutic challenges. This Review highlights the progress made and pitfalls encountered as the field continues to search for MDM-targeted antitumour agents.

Citing Articles

Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.

Sias F, Zoroddu S, Migheli R, Bagella L Int J Mol Sci. 2025; 26(5).

PMID: 40076599 PMC: 11900228. DOI: 10.3390/ijms26051973.

Unraveling the causal relationship and underlying mechanisms between cathepsins on liver cancer: findings from mendelian randomization and bioinformatics analysis.

Wang X, Zhu Z Discov Oncol. 2025; 16(1):277.

PMID: 40053224 PMC: 11889323. DOI: 10.1007/s12672-025-02030-3.

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A Mol Cancer. 2025; 24(1):58.

PMID: 40011944 PMC: 11863469. DOI: 10.1186/s12943-025-02267-0.

A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins.

Ganesan I, Kiyokawa H Cancers (Basel). 2025; 17(4).

PMID: 40002221 PMC: 11853300. DOI: 10.3390/cancers17040626.

USP38 functions as an oncoprotein by downregulating the p53 pathway through deubiquitination and stabilization of MDM2.

Zhao S, Liu X, Luo R, Jian Z, Xu C, Hou Y Cell Death Differ. 2025; .

PMID: 39987355 DOI: 10.1038/s41418-025-01462-2.

References

Park S, Shaffer A, Kim J, Dubois W, Potter M, Staudt L . Insertion of Myc into Igh accelerates peritoneal plasmacytomas in mice. Cancer Res. 2005; 65(17):7644-52. DOI: 10.1158/0008-5472.CAN-05-1222. View

Maya R, Balass M, Kim S, Shkedy D, Leal J, Shifman O . ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 2001; 15(9):1067-77. PMC: 312683. DOI: 10.1101/gad.886901. View

Vaseva A, Yallowitz A, Marchenko N, Xu S, Moll U . Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors. Cell Death Dis. 2011; 2:e156. PMC: 3122118. DOI: 10.1038/cddis.2011.39. View

Poyurovsky M, Priest C, Kentsis A, Borden K, Pan Z, Pavletich N . The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J. 2006; 26(1):90-101. PMC: 1782380. DOI: 10.1038/sj.emboj.7601465. View

Christophorou M, Ringshausen I, Finch A, Swigart L, Evan G . The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature. 2006; 443(7108):214-7. DOI: 10.1038/nature05077. View

Brennan R, Federico S, Bradley C, Zhang J, Flores-Otero J, Wilson M . Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res. 2011; 71(12):4205-13. PMC: 3116943. DOI: 10.1158/0008-5472.CAN-11-0058. View

Roxburgh P, Hock A, Dickens M, Mezna M, Fischer P, Vousden K . Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis. 2012; 33(4):791-8. DOI: 10.1093/carcin/bgs092. View

Whitesell L, Lindquist S . HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005; 5(10):761-72. DOI: 10.1038/nrc1716. View

Chen J, Li Y, Yu T, McKay R, Burns D, Kernie S . A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012; 488(7412):522-6. PMC: 3427400. DOI: 10.1038/nature11287. View

10.

Pant V, Xiong S, Iwakuma T, Quintas-Cardama A, Lozano G . Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci U S A. 2011; 108(29):11995-2000. PMC: 3141986. DOI: 10.1073/pnas.1102241108. View

11.

Post S, Quintas-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson J . A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010; 18(3):220-30. PMC: 2944041. DOI: 10.1016/j.ccr.2010.07.010. View

12.

Xiong S, Pant V, Suh Y, Van Pelt C, Wang Y, Valentin-Vega Y . Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. Cancer Res. 2010; 70(18):7148-54. PMC: 2940952. DOI: 10.1158/0008-5472.CAN-10-1457. View

13.

Sanchez M, Picard N, Sauve K, Tremblay A . Coordinate regulation of estrogen receptor β degradation by Mdm2 and CREB-binding protein in response to growth signals. Oncogene. 2012; 32(1):117-26. DOI: 10.1038/onc.2012.19. View

14.

Valentin-Vega Y, Box N, Terzian T, Lozano G . Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation. 2009; 77(5):442-9. PMC: 4041067. DOI: 10.1016/j.diff.2009.03.001. View

15.

Cohen P, Tcherpakov M . Will the ubiquitin system furnish as many drug targets as protein kinases?. Cell. 2010; 143(5):686-93. DOI: 10.1016/j.cell.2010.11.016. View

16.

Kadakia M, Brown T, McGorry M, Berberich S . MdmX inhibits Smad transactivation. Oncogene. 2002; 21(57):8776-85. DOI: 10.1038/sj.onc.1205993. View

17.

Wang X, Wei X, Thijssen B, Das J, Lipkin S, Yu H . Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat Biotechnol. 2012; 30(2):159-64. PMC: 3708476. DOI: 10.1038/nbt.2106. View

18.

Pereg Y, Lam S, Teunisse A, Biton S, Meulmeester E, Mittelman L . Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol Cell Biol. 2006; 26(18):6819-31. PMC: 1592859. DOI: 10.1128/MCB.00562-06. View

19.

Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S . The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7. PMC: 3320027. DOI: 10.1038/nature11003. View

20.

Wells J, McClendon C . Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007; 450(7172):1001-9. DOI: 10.1038/nature06526. View